Drugs / BMN 349
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06738017 | Feb 2025 → Aug 2026 overdue | alpha 1-antitrypsin deficiency | BioMarin Pharmaceutical | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMN 349 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06738017 ↗ |
| Route | Oral | “250mg oral tablet” NCT06738017 ↗ |